Resolution Therapeutics Reveals EMERALD Study Design
Resolution Therapeutics Ltd, a pioneering biopharmaceutical company, is at the forefront of innovation with its Regenerative Macrophage Therapy. The company has announced an exciting development regarding its EMERALD Phase I/II clinical trial, which focuses on utilizing RTX001 in the treatment of patients with end-stage liver disease. Chief Investigator, Professor Jonathan Fallowfield, is set to present the comprehensive study design at the British Association for the Study of the Liver (BASL) annual meeting in 2025.
Overview of the EMERALD Study
The EMERALD study is a significant multicenter Phase I/II clinical trial aimed at evaluating the safety and efficacy of RTX001. This innovative therapy is designed for patients suffering from advanced liver disease. A notable milestone for the study was the successful dosing of the first patient at the Royal Infirmary of Edinburgh, marking a key achievement for the clinical team and participants alike.
Initial Findings and Presentation Details
Professor Fallowfield, an authority in Translational Liver Research, will present a detailed poster on the study design, including critical insights into the trial's structure and expected outcomes. The study is characterized as a first-in-human, single-arm, open-label trial that aims to provide valuable data on the therapeutic potential of RTX001.
Poster Presentation Overview
Title: An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of RTX001 Autologous Macrophages in Patients with Liver Cirrhosis and Hepatic Decompensation (EMERALD)
Paper Reference: P68
Presenting Author: Professor Jonathan Fallowfield, University of Edinburgh
Date/Time: 8 October 2025, 6:00pm – 8:00pm BST
Recruitment and Study Objectives
The EMERALD study is fully open to recruitment, with a projected enrollment of up to 25 patients across various leading hepatology centers in the UK and Spain. This inclusiveness is designed to ensure robust data collection and diverse patient representation.
Expert Commentary on the Study
Dr. Clifford Brass, Chief Medical Officer at Resolution Therapeutics, emphasized the groundbreaking nature of this study, stating, "EMERALD represents the first exploration of engineered Regenerative Macrophage Therapy in patients with severe liver fibrosis. We are excited to present the study design at BASL and begin recruitment, providing hope to patients with limited therapeutic options."
Conference Participation
Dr. Faisal Sheikh, the medical director of Resolution Therapeutics, will also be present at the conference. Attendees interested in discussing the EMERALD study or learning more about the innovative therapies being developed are encouraged to reach out for a meeting.
Advancements in Regenerative Macrophage Therapy
Through its extensive research and development efforts, Resolution Therapeutics is committed to advancing regenerative medicine specifically targeting inflammatory and fibrotic diseases like end-stage liver disease. The company's lead product, RTX001, is engineered to enhance the natural regenerative capabilities of macrophages, aiming to deliver superior efficacy and patient outcomes.
About RTX001
RTX001 represents the forefront of therapeutic innovation, showcasing engineered autologous macrophages designed to exert enhanced anti-fibrotic and anti-inflammatory effects. This novel approach aims to transform patient care in liver diseases, with the EMERALD study serving as a critical vehicle for identifying its effectiveness.
Commitment to Patient Care
Beyond liver disease, Resolution Therapeutics is exploring applications for RTX001 and its regenerative platform in other conditions, including graft-vs-host disease (GVHD) and various forms of lung fibrosis. This broad vision positions the company as a key player in regenerative therapies.
About the British Association for the Study of the Liver (BASL)
The BASL serves as the premier national association for hepatology in the UK, aiming to elevate liver health through research, education, and collaboration. The association represents a diverse community of healthcare professionals united in the mission to enhance liver-related knowledge and care standards.
Frequently Asked Questions
What is the EMERALD study?
The EMERALD study is a Phase I/II clinical trial assessing the safety and efficacy of RTX001 in patients with end-stage liver disease.
Who is the Chief Investigator for EMERALD?
Professor Jonathan Fallowfield, Chair of Translational Liver Research at the University of Edinburgh, is the Chief Investigator guiding the EMERALD study.
When will the EMERALD study be presented?
The study design will be presented at the BASL annual meeting on October 8, 2025.
Where will the study take place?
The EMERALD study is being conducted in leading hepatology centers across the UK and Spain.
What outcomes does RTX001 aim to improve?
RTX001 is designed to enhance regenerative capabilities for better treatment outcomes in patients with liver diseases.
